Who is eligible for clinical trial NCT07234942?

Participants must meet protocol criteria for Alzheimer's Disease. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT07234942 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-07-28

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD) (NCT07234942)

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche

🩺 Plain-English Summary (8th-Grade Level)

This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).

Location: Toronto Western Hospital — Toronto, Ontario

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Probable AD dementia (consistent with National Institute on Aging and Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia) \[McKhann et al 2011\] or Mild Cognitive Impairment (MCI) due to AD (consistent with the NIA-AA core clinical criteria for mild cognitive impairment due to AD) \[Albert et al 2011\]).
Willingness and ability to complete all aspects of the study. The participant should be capable of completing assessments either alone or with the help of the study partner.
Fluency in the language of the tests used at the study site.
Adequate visual and auditory acuity, in the investigator's judgment, sufficient to perform the neuropsychological testing (eyewear and hearing aids are permitted).
If the participant is receiving symptomatic AD medications, a stable dosing regimen for at least 8 weeks prior to screening and until randomization is required.
Agreement not to participate in other research studies for the duration of this study.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Any medical history or evidence of a condition other than AD that may affect cognition.
Presence of any significant cerebral abnormalities that would contraindicate lumbar puncture, as assessed on MRI
Any other significant cerebral abnormalities that the Investigator considers clinically significant
History of schizophrenia, schizoaffective disorder, major depression or bipolar disorder.'
Presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological medical conditions which are not stable and adequately controlled or which in the opinion of the investigator could affect the subject's safety in the study or interfere with the study assessments

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (12 Sites)

Toronto Western Hospital — Toronto, Ontario
Montreal Neurological Institute Clinical Research Unit — Montreal, Quebec
Brain Research Center Amsterdam — Amsterdam, North Holland
Hospital General de Catalunya — Sant Cugat del Vallès, Barcelona
Hospital de la Santa Creu i Sant Pau — Barcelona,
Hospital Universitario Reina Sofia — Córdoba,
Sahlgrenska Universitetssjukhuset — Mlndal,
Karolinska Universitetssjukhuset — Solna,
Institute of Psychiatry, Psychology and Neuroscience;Department of Old Age Psychiatry — London, Greater London
Southampton General Hospital — Southampton, Hampshire
Queen Elizabeth Hospital — Glasgow, Strathclyde
National Hospital For Neurology and Neurosurgery — London,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗